The different roles of molecular classification according to upfront autologous stem cell transplantation in advanced-stage diffuse large B cell lymphoma patients with elevated serum lactate dehydrogenase

First-line rituximab (R) high-dose therapy (R-HDT) versus R-CHOP14 for young adults with diffuse large B-cell lymphoma: Preliminary results of the GOELAMS 075 prospective multicenter randomized trial.

(2017) S. Le Gouill et al.   JOURNAL OF CLINICAL ONCOLOGY

Non-Hodgkin’s Lymphomas, Version 4.2014

(2017) Andrew D. Zelenetz et al.   Journal of the National Comprehensive Cancer Network

Induction chemotherapy followed by up-front autologous stem cell transplantation may have a survival benefit in high-risk diffuse large B-cell lymphoma patients

(2016) Ho-Jin Shin et al.   EXPERIMENTAL HEMATOLOGY

Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL

(2015) F. Offner et al.   BLOOD

Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis

(2015) Christina Howlett et al.   BRITISH JOURNAL OF HAEMATOLOGY

Accurate Classification of Germinal Center B-Cell–Like/Activated B-Cell–Like Diffuse Large B-Cell Lymphoma Using a Simple and Rapid Reverse Transcriptase–Multiplex Ligation-Dependent Probe Amplification Assay

(2015) Sylvain Mareschal et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Everolimus-Eluting Stents or Bypass Surgery for Multivessel Coronary Disease

(2015) Sripal Bangalore et al.   NEW ENGLAND JOURNAL OF MEDICINE

Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue

(2014) D. W. Scott et al.   BLOOD

Double hit lymphoma: the MD Anderson Cancer Center clinical experience

(2014) Yasuhiro Oki et al.   BRITISH JOURNAL OF HAEMATOLOGY

Young Patients With Non–Germinal Center B-Cell–Like Diffuse Large B-Cell Lymphoma Benefit From Intensified Chemotherapy With ACVBP Plus Rituximab Compared With CHOP Plus Rituximab: Analysis of Data From the Groupe d'Etudes des Lymphomes de l'Adulte/Lymphoma Study Association Phase III Trial LNH 03-2B

(2014) Thierry Jo Molina et al.   JOURNAL OF CLINICAL ONCOLOGY

Autologous Transplantation as Consolidation for Aggressive Non-Hodgkin's Lymphoma

(2013) Patrick J. Stiff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study

(2012) C. Visco et al.   HAEMATOLOGICA

Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

(2012) Tina Marie Green et al.   JOURNAL OF CLINICAL ONCOLOGY

Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1)

(2012) Norbert Schmitz et al.   LANCET ONCOLOGY

Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy

(2011) G. Gutierrez-Garcia et al.   BLOOD

The Germinal Center/Activated B-Cell Subclassification Has a Prognostic Impact for Response to Salvage Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Bio-CORAL Study

(2011) Catherine Thieblemont et al.   JOURNAL OF CLINICAL ONCOLOGY

Evaluation of prognostic values of clinical and histopathologic characteristics in diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy

(2011) Junshik Hong et al.   LEUKEMIA & LYMPHOMA

Interim positron emission tomography scan associated with international prognostic index and germinal center B cell-like signature as prognostic index in diffuse large B-cell lymphoma

(2011) Hélène Lanic et al.   LEUKEMIA & LYMPHOMA

Standard International Prognostic Index Remains a Valid Predictor of Outcome for Patients With Aggressive CD20+B-Cell Lymphoma in the Rituximab Era

(2010) Marita Ziepert et al.   JOURNAL OF CLINICAL ONCOLOGY

Addition of Rituximab to Standard Chemotherapy Improves the Survival of Both the Germinal Center B-Cell–Like and Non–Germinal Center B-Cell–Like Subtypes of Diffuse Large B-Cell Lymphoma

(2008) Kai Fu et al.   JOURNAL OF CLINICAL ONCOLOGY